Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT)

Historical Holders from Q1 2014 to Q3 2025

Symbol
SRPT on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
106M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
86.8M
Holdings value
$1.67B
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
309
Number of buys
168
Number of sells
-208
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10.89% $191M 10.6M The Vanguard Group 29 Aug 2025
STATE STREET CORP 5.4% $102M 5.3M STATE STREET CORPORATION 30 Sep 2025
D. E. SHAW & CO, L.P. 1.9% -64% $38.7M -$58.8M 2.01M -60.3% D. E. Shaw & Co., L.P. 30 Sep 2025
Capital International Investors 0.5% -97.8% $9.52M -$152M 524K -94.1% Capital International Investors 30 Jun 2025

Institutional Holders of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 86.8M $1.67B +$92.8M $19.27 309
2025 Q2 82.8M $1.41B -$616M $17.10 354
2025 Q1 85.7M $5.48B -$372M $63.82 419
2024 Q4 87.8M $10.7B +$115M $121.59 459
2024 Q3 86.8M $10.8B -$452M $124.89 451
2024 Q2 88.8M $14B +$923M $158.00 479
2024 Q1 83.2M $10.8B +$210M $129.46 408
2023 Q4 81.6M $7.87B -$295M $96.43 386
2023 Q3 83.3M $10.1B +$213M $121.22 390
2023 Q2 81.7M $9.36B +$62.4M $114.52 399
2023 Q1 81.2M $11.2B +$325M $137.83 422
2022 Q4 78.9M $10.2B +$92.9M $129.58 405
2022 Q3 78.3M $8.65B +$569M $110.54 364
2022 Q2 73.3M $5.5B +$36M $74.96 312
2022 Q1 73M $5.71B +$56.4M $78.12 314
2021 Q4 71.9M $6.47B +$536M $90.05 326
2021 Q3 65.8M $6.08B +$130M $92.48 297
2021 Q2 64.8M $5.04B -$83.6M $77.74 315
2021 Q1 66.3M $4.94B -$714M $74.53 346
2020 Q4 70.6M $12B -$160M $170.49 435
2020 Q3 72.1M $10.1B -$336M $140.43 393
2020 Q2 73.9M $11.8B +$151M $160.34 397
2020 Q1 73.4M $7.18B -$46.3M $97.82 346
2019 Q4 73.5M $9.48B +$56.2M $129.04 379
2019 Q3 73.2M $5.52B -$252M $75.32 329
2019 Q2 71.7M $10.9B +$292M $151.95 359
2019 Q1 71.1M $8.48B +$291M $119.19 359
2018 Q4 68.7M $7.49B +$727M $109.13 325
2018 Q3 61.2M $9.88B +$246M $161.51 336
2018 Q2 60M $7.92B +$549M $132.18 311
2018 Q1 56.8M $4.2B +$182M $74.09 265
2017 Q4 55.2M $3.07B +$54.9M $55.64 246
2017 Q3 53.7M $2.44B +$526M $45.36 229
2017 Q2 42.7M $1.44B +$80.8M $33.71 186
2017 Q1 40.7M $1.21B +$221M $29.60 177
2016 Q4 39.4M $1.08B -$176M $27.43 175
2016 Q3 42.4M $2.6B +$579M $61.41 183
2016 Q2 34.6M $660M -$14.4M $19.07 142
2016 Q1 35.1M $686M +$88.7M $19.52 129
2015 Q4 28.5M $1.1B +$34.4M $38.58 146
2015 Q3 27.8M $892M +$36.6M $32.11 145
2015 Q2 26.7M $811M +$87.3M $30.43 127
2015 Q1 24.2M $321M -$7.5M $13.28 111
2014 Q4 24.7M $357M -$43.9M $14.47 118
2014 Q3 26M $548M -$18.5M $21.10 121
2014 Q2 26.7M $794M +$1.2M $29.79 126
2014 Q1 26.6M $639M -$12.4M $24.03 114